Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu-city, Mie, 514-8507, Japan.
Curr Oncol Rep. 2022 May;24(5):563-571. doi: 10.1007/s11912-022-01244-w. Epub 2022 Feb 22.
Surgical resection is the standard treatment for localized soft tissue sarcoma (STS), while systemic chemotherapy for advanced STS may be considered. However, less aggressive treatment is often administered to elderly patients with STS. Undertreatment may compromise the cure rate and survival of these individuals. We review the literatures and emphasize the importance of standard treatment for STS in elderly patients.
The outcome of surgical resection of STS in older individuals is comparable to that of younger ones, as long as patients are selected based on American Society of Anesthesiologists Physical Status (ASA-PS). Likewise, systemic treatment may prove beneficial as long as the risk of complications is estimated with a geriatric assessment. Elderly patients with STS benefit from standard treatment as long as the risks of surgical and systemic complications are assessed respectively with the ASA-PS and GA. Novel clinical trials with broader eligibility criteria are also necessary for elderly patients because of the increasing population of the elderly patients in the future.
手术切除是局限性软组织肉瘤（STS）的标准治疗方法，而晚期 STS 的系统化疗可能也被考虑。然而，对患有 STS 的老年患者常采用侵袭性较小的治疗方法。治疗不足可能会降低这些患者的治愈率和生存率。我们回顾了文献并强调了对老年 STS 患者进行标准治疗的重要性。
只要根据美国麻醉医师协会身体状况（ASA-PS）对患者进行选择，老年 STS 患者手术切除的结果与年轻患者相当。同样，只要通过老年评估来估计并发症的风险，系统治疗也可能是有益的。只要分别使用 ASA-PS 和 GA 来评估手术和全身并发症的风险，老年 STS 患者就可以从标准治疗中获益。对于未来老年患者人数不断增加的情况，也需要有更广泛的纳入标准的新型临床试验。
